Indaptus Therapeutics, Inc. (INDP) - Dilution Analysis

10-K filing | 2.2M shares outstanding

8-K filing: Indaptus, Inc. entered into a Securities Purchase Agreement with David E. Lazar to sell Series AA and Series AAA Convertible Preferred Stock for $6.0 million, with each share convertible into Common Stock, and filed the certificates of designation for the preferred stock. ($6.0M proceeds)

S-1/A filing: Amendment to a previously filed S-1 form.

S-3 filing: Indaptus Therapeutics, Inc. may offer and sell up to $200,000,000 of its common stock, preferred stock, subscription rights, debt securities, warrants and a combination of such securities.

S-3 filing: This S-3 filing relates to the proposed resale or other disposition of up to 2,160,166 shares of common stock by the selling stockholders of Indaptus Therapeutics Inc.

10-Q filing | 1.1M shares outstanding

8-K filing: Indaptus Therapeutics, Inc. completed a private placement of convertible promissory notes and warrants, and subsequently converted the notes into common stock and issued warrants and pre-funded warrants.

8-K filing: Stock split 1-for-28 | Outstanding: 16,034,444 → 572,658

10-Q filing | 16.0M shares outstanding

POS AM filing: Indaptus Therapeutics, Inc. is offering up to 10,000,000 shares of common stock through a selling stockholder and may receive up to $20.0 million in aggregate gross proceeds from sales of shares to YA under a Standby Equity Purchase Agreement.

10-K filing | 14.4M shares outstanding

S-1 filing: Indaptus Therapeutics, Inc. is offering 10,000,000 shares of common stock through a selling stockholder, YA II PN, LTD., pursuant to a Standby Equity Purchase Agreement, with the company potentially receiving up to $20.0 million in gross proceeds from sales of shares to YA.

8-K filing: Indaptus Therapeutics, Inc. entered into a Standby Equity Purchase Agreement with YA II PN, LTD. (Yorkville) for up to $20.0 million of the Company's common stock over 36 months, issuing 305,960 Commitment Shares to Yorkville and paying a $25,000 structuring fee.

S-3 filing: This prospectus relates to the proposed resale or other disposition of up to 4,366,422 shares of common stock by selling stockholders.

8-K filing: Indaptus Therapeutics, Inc. entered into securities purchase agreements for the sale and issuance of 2,109,383 shares of common stock and warrants to purchase 2,109,383 shares of common stock in a private placement for aggregate gross proceeds of $2,246,500. ($2.25M proceeds)

S-1 filing: This S-1 filing relates to the proposed resale of up to 1,941,229 shares of common stock by selling stockholders, consisting of shares issuable upon the exercise of investor and placement agent warrants from a November 2024 private placement.

8-K filing: Indaptus Therapeutics, Inc. sold 1,817,017 shares of common stock and warrants to purchase 1,817,017 shares of common stock at a combined price of $1.175 per share and warrant, along with issuing warrants to Paulson Investment Company, LLC to purchase 124,212 shares of common stock at an exercise price of $1.3125 as compensation for placement agent services. ($2.14M proceeds)

10-Q filing | 9.5M shares outstanding

S-1 filing: This prospectus relates to the proposed resale or other disposition of up to 1,643,837 shares of common stock issuable upon the exercise of warrants to purchase shares of common stock.

10-Q filing | 10.2M shares outstanding

8-K filing: Indaptus Therapeutics, Inc. entered into securities purchase agreements to sell 1,643,837 shares of common stock and warrants to purchase 1,643,837 shares of common stock at a combined price of $1.825 per share and warrant.

10-Q filing | 8.4M shares outstanding

10-K filing | 8.4M shares outstanding

10-Q filing | 8.4M shares outstanding

10-Q filing | 8.4M shares outstanding

10-Q filing | 8.4M shares outstanding

10-K filing | 8.3M shares outstanding

8-K filing: Indaptus Therapeutics, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, pursuant to which Lincoln Park has committed to purchase up to $20.0 million of the Company's common stock, and the Company issued 142,450 shares of common stock to Lincoln Park as initial commitment shares.

S-1 filing: Indaptus Therapeutics, Inc. is offering up to 4,000,000 shares of common stock through Lincoln Park Capital Fund, LLC, with the potential for the company to receive up to $20.0 million in gross proceeds from sales of common stock to Lincoln Park under a purchase agreement.

10-Q filing | 8.3M shares outstanding

RW filing: Indaptus Therapeutics, Inc. is withdrawing a registration statement on Form S-3 (File No. 333-265350) for the offering, issuance and sale of common stock, preferred stock, subscription rights, debt securities, warrants and units, which together shall have an aggregate initial offering price not to exceed $200,000,000.

S-3 filing: Indaptus Therapeutics, Inc. may offer, issue and sell from time to time up to $200,000,000 of its common stock, preferred stock, subscription rights, debt securities, warrants and a combination of such securities, separately or as units, in one or more offerings.

10-Q filing | 8.3M shares outstanding

S-3 filing: Indaptus Therapeutics, Inc. may offer, issue and sell from time to time up to $200,000,000 of its common stock, preferred stock, subscription rights, debt securities, warrants and a combination of such securities, separately or as units, in one or more offerings.

10-Q filing | 8.3M shares outstanding

POS AM filing: This prospectus relates to the resale of up to 5,590,910 shares of common stock by selling stockholders.

10-K filing | 8.3M shares outstanding

POS AM filing: This prospectus relates to the resale of an aggregate of up to 5,590,910 shares of common stock by the selling stockholders.

10-Q filing | 8.2M shares outstanding

RW filing: Indaptus Therapeutics, Inc. is withdrawing the Registration Statement on Form S-3 (File No. 333-258854) filed on August 16, 2021, for the offer and resale of up to 5,590,910 shares of common stock because the Company has opted to include the Shares in the Registration Statement on Form S-1 (File No. 333-259771).

S-1 filing: This S-1 filing relates to the resale of up to 5,590,910 shares of common stock by selling stockholders, issuable upon the exercise of warrants from a private placement on August 3, 2021.

S-3 filing: Indaptus entered into a securities purchase agreement to sell and issue a pre-funded warrant and a warrant to purchase common stock in a private placement.

10-Q filing | 5406.0M shares outstanding

8-K filing: Intec Parent closed a private placement on August 3, 2021, selling a pre-funded warrant to purchase up to 2,727,273 shares of common stock and a warrant to purchase up to 2,727,273 shares of common stock at $10.99 per pre-funded warrant and associated warrant, for aggregate gross proceeds of approximately $29.9 million. ($59.8M proceeds)

8-K filing: Intec Parent, Inc. entered into a securities purchase agreement to sell pre-funded warrants and warrants for common stock, resulting in gross proceeds of approximately $29.9 million, and Intec Israel implemented a 1-for-4 reverse share split effective July 26, 2021. ($59.8M proceeds)

10-Q filing | 0.0M shares outstanding